Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levocetirizine + tranexamic acid
- Development stage
- Preclinical
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two medications: levocetirizine, a second-generation H1-receptor antagonist (antihistamine), and tranexamic acid, an antifibrinolytic agent. Levocetirizine works by selectively inhibiting histamine H1 receptors, preventing histamine from causing allergic symptoms. Tranexamic acid competitively inhibits the activation of plasminogen to plasmin, preventing the breakdown of blood clots and reducing bleeding. This combination has been studied for treating chronic spontaneous urticaria.
02
Targets
PLG (Plasminogen)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on levocetirizine + tranexamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levocetirizine + tranexamic acid.